<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01784445</url>
  </required_header>
  <id_info>
    <org_study_id>PEP 2013</org_study_id>
    <nct_id>NCT01784445</nct_id>
  </id_info>
  <brief_title>Post ERCP Pancreatitis Prevention in Average Risk Patients</brief_title>
  <official_title>Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Rijeka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Rijeka</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diclophenac potassium and ceftazidime are commercially available drugs that are used in
      various clinical situations. They are safe and known for years. Diclophenac potassium and
      Ceftazidime have been used in some studies for the prophylaxis and treatment of pancreatitis
      and Post-ERCP Pancreatitis (PEP). Diclophenac potassium, together with indometacin is
      currently standard treatment for prevention of (PEP) while ceftazidime is possible
      alternative treatment for patients with contraindications for nonsteroidal medicines. The aim
      of the study is to evaluate the efficacy of Ceftazidime for the prophylaxis of PEP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study type:

      Interventional Allocation: Randomized Endpoint Classification: Efficacy Study Intervention
      Model: Parallel Assignment Masking: only Investigator Primary Purpose: Prevention Study
      Phase: Phase 4

      Conditions or Focus of the study: Post ERCP pancreatitis

      Intervention information

        -  Intervention Names ERCP

        -  Arm Information

             -  Arm 1:Ceftazidime

             -  Arm 2 (active comparator): Diclophenac potassium
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of PEP in the group of patients receiving Ceftazidime versus incidence of PEP in the group of patients receiving Diclophenac potassium</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Time to discharge from hospital</measure>
    <time_frame>One year</time_frame>
    <description>Influence of PEP severity on time to discharge from hospital</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Ceftazidime plus placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Procedure/Surgery: ERCP Each patient will receive: Ceftazidime 2 g i.v. once daily 30 minutes prior to procedure and glycerin suppository as placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclophenac sodium plus placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure/Surgery:ERCP Each patient will receive 100 mg Diclophenac suppositories, once daily immediately prior to procedure plus 100 ml of saline as placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftazidime</intervention_name>
    <description>Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure</description>
    <arm_group_label>Ceftazidime plus placebo</arm_group_label>
    <arm_group_label>Diclophenac sodium plus placebo</arm_group_label>
    <other_name>Fortaz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  o All patients undergone to ERCP irrespectively about the diagnosis

        Exclusion Criteria:

          -  o Unwillingness or inability to consent for the study

               -  Age &lt; 18 years

               -  Previous ERCP (papillotomy)

               -  Intrauterine pregnancy

               -  Breast feeding mother

               -  Allergy to Aspirin or NSAIDs and Ceftazidime

               -  NSAID or antibiotic use within 1 week (ASA 325 mg daily or less acceptable)

               -  Renal failure (Cr &gt; 1.4)

               -  Active or recent (within 4 weeks) gastrointestinal hemorrhage

               -  Existing acute pancreatitis (lipase peak) within 72 hours prior to ERCP

               -  Anticipated inability to follow protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Hauser, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Rijeka</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Centre</name>
      <address>
        <city>Rijeka</city>
        <state>Kresimirova 42</state>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2013</study_first_submitted>
  <study_first_submitted_qc>February 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2013</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Rijeka</investigator_affiliation>
    <investigator_full_name>Goran Hauser</investigator_full_name>
    <investigator_title>Goran Hauser, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Endoscopic Retrograde Cholangiopancreatography,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

